Main lines of research of cholangiocarcinoma

Cholangiocarcinoma is a very heterogeneous disease, in terms of the genetic mechanisms that determine its appearance. In recent years, there have been advances in the knowledge about these molecular pathways, which have allowed the development of drugs that act in a targeted way on these alterations. For this reason, genetic studies are performed on tumour tissue samples to determine these mutations and evaluate new drugs. The Hospital Clínic Hepatic Oncology Unit is a reference for this disease, and new drugs can be accessed in the context of clinical trials at the onset of advanced disease, and after progressing to standard treatment, patients have the option of participating in early-stage clinical trials..